A detailed history of Jump Financial, LLC transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Jump Financial, LLC holds 24,940 shares of KURA stock, worth $242,915. This represents 0.01% of its overall portfolio holdings.

Number of Shares
24,940
Previous 38,071 34.49%
Holding current value
$242,915
Previous $783,000 37.8%
% of portfolio
0.01%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$18.57 - $23.23 $243,842 - $305,033
-13,131 Reduced 34.49%
24,940 $487,000
Q2 2024

Aug 14, 2024

SELL
$17.53 - $22.98 $131,860 - $172,855
-7,522 Reduced 16.5%
38,071 $783,000
Q1 2024

May 13, 2024

BUY
$13.42 - $23.53 $611,858 - $1.07 Million
45,593 New
45,593 $972,000
Q3 2023

Oct 21, 2024

BUY
$8.44 - $11.86 $317,977 - $446,825
37,675 Added 315.56%
49,614 $452,000
Q3 2023

Nov 07, 2023

BUY
$8.44 - $11.86 $418,742 - $588,422
49,614 New
49,614 $452,000
Q1 2023

Oct 21, 2024

SELL
$10.71 - $14.6 $279,873 - $381,527
-26,132 Reduced 68.64%
11,939 $146,000
Q1 2023

May 03, 2023

BUY
$10.71 - $14.6 $127,866 - $174,309
11,939 New
11,939 $146,000
Q3 2022

Nov 07, 2022

BUY
$12.01 - $19.45 $615,404 - $996,637
51,241 New
51,241 $700,000
Q3 2021

Nov 12, 2021

SELL
$15.42 - $21.72 $164,994 - $232,404
-10,700 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$20.85 - $29.88 $223,095 - $319,716
10,700 New
10,700 $223,000
Q1 2021

May 17, 2021

SELL
$24.75 - $39.14 $188,100 - $297,464
-7,600 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$29.0 - $41.62 $220,400 - $316,312
7,600 New
7,600 $248,000

Others Institutions Holding KURA

About Kura Oncology, Inc.


  • Ticker KURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,893,000
  • Market Cap $652M
  • Description
  • Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...
More about KURA
Track This Portfolio

Track Jump Financial, LLC Portfolio

Follow Jump Financial, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jump Financial, LLC with notifications on news.